Recent Promotions
MIF Knockout MC-38 Cell Line
Cat.No.:
EDJ-KZ349
Species:
Mouse
Cell Name:
MC-38
Gene:
MIF
Gene ID:
17319
Size:
1×10⁶cells
MIF Knockout MC-38 Cell Line is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performotion Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDJ-KZ349 |
|---|---|
| Product Name | MIF Knockout MC-38 Cell Line |
| Species | Mouse |
| Cell Line | MC-38 |
| Gene | |
| Morphology | Adherent |
| Passage Ratio | 1/3,2 days |
| Complete Culture Medium | DMEM + 10% FBS |
| Freezing Medium | 50% Complete medium + 40% FBS + 10DMSO |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: MC-38 | STR Info (Cell bank) Cell Line: MC-38 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| 1-1 | 16 | 16 | ||
| 1-2 | 19 | 19 | ||
| 2-1 | 16 | 16 | ||
| 3-2 | 13 | 14 | 13 | 14 |
| 4-2 | 20.3 | 20.3 | ||
| 5-5 | 17 | 17 | ||
| 6-4 | 18 | 18 | ||
| 6-7 | 14 | 15 | 14 | 15 |
| 7-1 | 26.2 | 26.2 | ||
| 8-1 | 16 | 17 | 16 | 17 |
| 11-2 | 16 | 16 | ||
| 12-1 | 17 | 17 | ||
| 13-1 | 17.1 | 17.1 | ||
| 15-3 | 22.3 | 22.3 | ||
| 17-2 | 15 | 15 | ||
| 18-3 | 16 | 16 | ||
| 19-2 | 13 | 13 | ||
| X-1 | 27 | 27 | ||
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
Research Publications
Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1.
IF=6.1
JCI insight
This KO model may be useful for:
- Investigating the role of MIF in immune checkpoint blockade resistance
- Evaluating combination therapies targeting MIF and PD-1 for enhanced immunotherapy responses
- Studying MIF-mediated tumor immune evasion mechanisms
- Functional validation of MIF as a therapeutic target in syngeneic mouse models
- Preclinical screening of MIF inhibitors in an immunocompetent tumor microenvironment